IONS: FDA Clears Tryngolza

S. ’s (NASDAQ: IONS ) Tryngolza (olezarsen) to treat severe hypertriglyceridemia. • Ionis Pharmaceuticals stock is moving in positive territory. Why are IONS shares climbing?

S. S. launch of zilganersen later this year. Read Also: Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market FDA Clears TRYNGOLZA for Severe Hypertriglyceridemia The FDA approved Tryngolza as an adjunct to diet to lower triglyceride levels and reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia, defined as triglyceride levels of at least 500 mg/dL.

The therapy, available in 50 mg and 80 mg doses, is administered once monthly through an autoinjector. The approval was supported by data from the Phase 3 CORE and CORE2 studies In the studies, Tryngolza lowered fasting triglyceride levels by as much as 72% versus placebo after six months, with reductions maintained through 12 months. The treatment also cut acute pancreatitis events by up to 91%. Among patients with baseline and one-year data, 86% achieved triglyceride levels below 500 mg/dL, a threshold associated with lower pancreatitis risk.

S. in July. S. S.

and continue leading global development efforts, while Recordati will oversee regulatory filings and commercialization activities internationally. Zilganersen, currently under FDA review with a Prescription Drug User Fee Act action date of Sept. S. Pivotal Study Data Supports Zilganersen Filing Ionis recently reported additional positive data from the pivotal Zilganersen study.

The trial met its primary endpoint in patients aged five years and older. The 50 mg dose produced statistically significant stabilization in gait speed at week 61 compared with controls. Secondary and exploratory measures also favored treatment with Zilganersen. The investigational therapy demonstrated a favorable safety profile, with most adverse events classified as mild or moderate.

Ionis will receive a $30 million upfront payment and remain eligible for milestone payments and tiered royalties reaching the mid-20% range on annual net sales. ” Analyst Myles Minter reiterated the Outperform rating. 28 at the time of publication on Thursday, according to Pro data. Photo: Shutterstock Read Also: 'Big Short' Star Steve Eisman Warns Middle Class Is 'Starting To Crack', Tax Refunds 'Went Into The Gas Tank'